The frequency of diagnosis of inflammatory bowel disease(IBD) has increased in younger populations.For this reason,pregnancy in patients with IBD is a topic of interest,warranting additional focus on disease management during this period.The main objective of this article is to summarize the latest findings and guidelines on the management of potential problems from pregnancy to the breastfeeding stage.Fertility is decreased in patients with active IBD.Disease remission prior to conception will likely decrease the rate of pregnancy-related complications.Most of the drugs used for IBD treatment are safe during both pregnancy and breastfeeding.Two exceptions are methotrexate and thalidomide,which are contraindicated in pregnancy.Antitumor necrosis factor agents are not advised during the third trimester as they exhibit increased transplacental transmission and potentially cause immunosuppression in the fetus.Radiological and endoscopic examinations and surgical interventions should be performed only when absolutely necessary.Surgery increases the fetal mortality rate.The delivery method should be determined with consideration of the disease site and presence of progression or flare up.Treatment planning should be a collaborative effort among the gastroenterologist,obstetrician,colorectal surgeon and patient. The frequency of diagnosis of inflammatory bowel disease (IBD) has increased in younger populations. For this reason, pregnancy in patients with IBD is a topic of interest, warranting additional focus on disease management during this period. Main article of this article is to summarize the latest findings and guidelines on the management of potential problems from pregnancy to the breastfeeding stage. Fertility is decreased in patients with active IBD. Disease remission prior to conception will likely decrease the rate of pregnancy-related complications. Host of the drugs used for IBD treatment are safe during both pregnancy and breastfeeding. Both exceptions are methotrexate and thalidomide, which are contraindicated in pregnancy. Antitumor necrosis factor agents are not advised during the third trimester as they exhibit increased transplacental transmission and potentially cause immunosuppression in the fetus. Radiological and endoscopic examinations and surgical interventions should be pe rformed only when absolutely necessary. Surgry increases the fetal mortality rate. The delivery method should be determined with consideration of the disease site and presence of progression or flare up. Treatment planning should be a collaborative effort among the gastroenterologist, obstetrician, colorectal surgeon and patient .